The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and… Read More
Olipudase alfa has been granted PRIority MEdicines (PRIME) designation in Europe, Breakthrough Therapy designation in the United States, and SAKIGAKE designation in Japan. European regulatory decision anticipated second half of… Read More
Actemra/RoActemra reduced the risk of death in patients with severe COVID-19, as evidenced by a review of four phase III studies The European Commission is expected to make a final decision… Read More
Molnupiravir will be manufactured at Thermo Fisher Scientific’s site in Whitby, ON KIRKLAND, QC – Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today it… Read More
Expanded EUA includes both treatment of patients with COVID-19 and post-exposure prophylaxis (PEP) in pediatric and infant patients VANCOUVER, BC – AbCellera (Nasdaq: ABCL) today announced the U.S. Food and Drug… Read More
